CClinicalTrials.gg
CompletedNCT01262131Updated Jul 1, 2011Results posted

Evaluation of Magnetic Fields to Treat Fibromyalgia

A Phase 2 interventional study of magnetic therapy protocol A and magnetic therapy Protocol B in Fibromyalgia, sponsored by pico-tesla Magnetic Therapies, LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-01.

Sponsored by pico-tesla Magnetic Therapies, LLC · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to see if a device called the Resonator can help to reduce pain and improve aspects of health and quality of life for people with fibromyalgia.

Read the detailed description

The purpose of this pilot study is to assess the efficacy of the Resonator device as an adjunctive therapy to reducing pain and improving aspects of health and quality of life that are relevant to individuals with fibromyalgia.

02

Conditions studied

  • Fibromyalgia

Keywords

  • Fibromyalgia
  • Pain associated with Fibromyalgia
03

In context

Fibromyalgia

1,336 studies on the registry are indexed under Fibromyalgia; 266 are open to participants now.

This study's enrollment of 13 is below the median of 60 across 1,035 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

pico-tesla Magnetic Therapies, LLC is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
  • Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater.
  • Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation.
  • Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation.
  • Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation.
  • Willing and able to refrain from use of tender point injections throughout study participation.
  • Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation.
  • Adequate contraceptive measures for female subjects. > 18 years of age or older.
  • Male or female.

Exclusion criteria

Exclusion Criteria:

  • Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures.
  • Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia.
  • Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools.
  • Tender point injections received within the prior one month.
  • Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse).
  • Known inflammatory rheumatic disease.
  • Epilepsy/history of seizures/taking medication for epilepsy.
  • HIV and other autoimmune disorders.
  • Active cancer or treatment for cancer within last 6 months.
  • Active infection(s).
  • History of ECT
  • Uncontrolled Hypertension.
  • Advanced Pulmonary Disease.
  • Unstable cardiac disease.
  • Prosthetics or implants comprised of ferrous metals.
  • Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
  • Consumption of more than 21 alcoholic drinks per week.
  • Pregnant, breast feeding, or planning pregnancy prior to end of study participation.
  • Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities.
  • Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition.
  • Participation in other research within 30 days of study enrollment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Resonator Protocol A

    Device: magnetic therapy protocol A

  • Active comparator
    Resonator Protocol B

    Application of magnetic fields using the Resonator device Protocol B

    Device: magnetic therapy Protocol B

  • Placebo comparator
    Inactive Resonator

    Device: placebo therapy

Interventions

  • Devicemagnetic therapy protocol A

    Application of magnetic fields using the Resonator device Protocol A

  • Devicemagnetic therapy Protocol B

    Application of magnetic fields using the Resonator device Protocol B

  • Deviceplacebo therapy

    Application of inactive magnetic fields using the Resonator device

06

What researchers measure

Primary outcomes

  1. Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.

    Minimum scale value is '0' which represents 'no pain at all' and is the best outcome. Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.

    Time frame: 2 weeks (baseline to end of treatment)

07

Results

Posted Jul 1, 2011

Participant flow

Participant flow — Overall Study
MilestoneResonator Protocol AResonator Protocol BInactive Resonator
Started544
Completed544
Not completed000

Outcome measures

PrimaryMean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.

Minimum scale value is '0' which represents 'no pain at all' and is the best outcome. Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.

Time frame:
2 weeks (baseline to end of treatment)
Reported as:
Mean · Scores on a scale
Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
Scores on a scaleResonator Protocol AResonator Protocol BInactive Resonator
Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.-3.69 ± 1.2-3.08 ± 1.2-1.97 ± 1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Resonator Protocol A—0/5 (0%)0/5 (0%)
Resonator Protocol B—0/4 (0%)0/4 (0%)
Inactive Resonator—0/4 (0%)0/4 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Resonator Protocol AResonator Protocol BInactive ResonatorTotal
<=18 years0000
Between 18 and 65 years54413
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Resonator Protocol AResonator Protocol BInactive ResonatorTotal
Female54413
Male0000
08

Study locations

No study locations are listed for this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01262131
Lead sponsor
pico-tesla Magnetic Therapies, LLC
First posted
Dec 17, 2010
Start date
Dec 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Jul 1, 2011
Last update
Jul 1, 2011

Study contacts

Jerry I Jacobson, Ph.D, D.M.D.
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion